SCHEMBL16234936

SCHEMBL16234936

Cc1ncc(S(=O)(=O)Nc2cncc(Cl)c2O)cc1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.45
▸ MAPT P10636 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ GAA P10253 5/20 0.41
▸ ALOX15 P16050 3/20 0.41
▸ HSD17B10 Q99714 3/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ HPGD P15428 1/20 0.41
▸ NPC1 O15118 1/20 0.40
▸ HSP90AA1 P07900 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ ADAM17 P78536 1/20 0.40
▸ KLF5 Q13887 1/20 0.40
▸ CCR2 P41597 4/20 0.39
▸ CYP3A4 P08684 2/20 0.39
▸ CYP2C9 P11712 2/20 0.39
▸ CYP2C19 P33261 2/20 0.39
▸ CCR4 P51679 1/20 0.39
▸ HTT P42858 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16235055 0.82 ALDH1A1 (0.47) ALDH1A1MAPTGAAALOX15HSD17B10
SCHEMBL28053260 0.81 ACLY (0.51) ALDH1A1GAAALOX15HSD17B10MEN1
SCHEMBL16235520 0.81 ALDH1A1 (0.52) ALDH1A1MAPTNPSR1GAAKMT2A
SCHEMBL16235193 0.79 S100A9 (0.48) CYP3A4S100A9
SCHEMBL16235391 0.78 S100A9 (0.57) ALDH1A1GAAALOX15HSD17B10MEN1
SCHEMBL16235253 0.78 S100A9 (0.62) ALDH1A1KMT2ACCR2CYP3A4CYP2C9
SCHEMBL16235621 0.77 S100A9 (0.49) ALDH1A1MAPTNPSR1GAAHSD17B10
SCHEMBL16235161 0.76 ALDH1A1 (0.54) ALDH1A1MAPTGAAMEN1KMT2A
SCHEMBL16235516 0.76 S100A9 (0.44) CCR2S100A9
SCHEMBL16235689 0.76 S100A9 (0.48) ALDH1A1MAPTNPSR1KMT2ACCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220378763-A1 COMPOUND FOR TREATMENT OF ACUTE INFLAMMATION IN THE MYOCARDIUM CALPROTECT AB (SE) 2022-12-01 — — US claimed
WO-2020260692-A1 COMPOUND FOR TREATMENT OF ACUTE INFLAMMATION IN THE MYOCARDIUM CALPROTECT AB (SE) 2020-12-30 — — WO claimed
US-10125125-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors ACTIVE BIOTECH AB (SE) 2018-11-13 — — US claimed
US-20180155330-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2018-06-07 — — US claimed
US-9873687-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors ACTIVE BIOTECH AB (SE) 2018-01-23 — — US claimed
US-20160115158-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2016-04-28 — — US claimed
EP-2925743-B1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2016-02-03 — — EP claimed
EP-2925743-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS Active Biotech AB (SE) 2015-10-07 — — EP claimed
WO-2014184234-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2014-11-20 — — WO claimed
US-20220378763-A1 COMPOUND FOR TREATMENT OF ACUTE INFLAMMATION IN THE MYOCARDIUM CALPROTECT AB (SE) 2022-12-01 — — US disclosed
WO-2020260692-A1 COMPOUND FOR TREATMENT OF ACUTE INFLAMMATION IN THE MYOCARDIUM CALPROTECT AB (SE) 2020-12-30 — — WO disclosed
US-10125125-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors ACTIVE BIOTECH AB (SE) 2018-11-13 — — US disclosed
US-20180155330-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2018-06-07 — — US disclosed
US-20180155330-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2018-06-07 — — US disclosed
US-20160115158-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2016-04-28 — — US disclosed
EP-2925743-B1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2016-02-03 — — EP disclosed
EP-2925743-B1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2016-02-03 — — EP disclosed
EP-2925743-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS Active Biotech AB (SE) 2015-10-07 — — EP disclosed
WO-2014184234-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2014-11-20 — — WO disclosed
WO-2014184234-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2014-11-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220378763-A1 COMPOUND FOR TREATMENT OF ACUTE INFLAMMATION IN THE MYOCARDIUM TNNT2, TNNI3, HMGB1 ALDH1A1 2241/4885MAPT 2922/4885NPSR1 3521/4885
US-10125125-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors S100A9, S100B, S100A10 ALDH1A1 4109/4885MAPT 380/4885NPSR1 1647/4885
US-20180155330-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS S100A9, S100B, S100A10 ALDH1A1 4109/4885MAPT 380/4885NPSR1 1647/4885
US-20160115158-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS S100A9, S100A4, S100B ALDH1A1 4370/4885MAPT 311/4885NPSR1 1917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback